These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 32776298)

  • 21. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19.
    Wu L; Zheng Y; Liu J; Luo R; Wu D; Xu P; Wu D; Li X
    Aging (Albany NY); 2021 Apr; 13(8):10833-10852. PubMed ID: 33879634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
    Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Clin Microbiol Infect; 2021 Dec; 27(12):1826-1837. PubMed ID: 34048876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19.
    Mohsenian Naghani S; Jansen MM; Jaspers T; Bastiaans D; Burger D
    Eur J Hosp Pharm; 2023 Mar; 30(e1):e106-e108. PubMed ID: 33990390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.
    Simpson KN; Pei PP; Möller J; Baran RW; Dietz B; Woodward W; Migliaccio-Walle K; Caro JJ
    Pharmacoeconomics; 2013 May; 31(5):427-44. PubMed ID: 23620210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19.
    Karolyi M; Omid S; Pawelka E; Jilma B; Stimpfl T; Schoergenhofer C; Laferl H; Seitz T; Traugott M; Wenisch C; Zoufaly A
    Front Pharmacol; 2021; 12():704767. PubMed ID: 34276386
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2.
    Liu J; Du C; Pu L; Xiang P; Xiong H; Xie W; Chen Z; Li A
    BMC Infect Dis; 2021 Aug; 21(1):885. PubMed ID: 34461841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
    Joseph BA; Dibas M; Evanson KW; Paranjape G; Vegivinti CTR; Selvan PT; Saravu K; Gupta N; Pulakurthi YS; Keesari PR; Varsha S; Chittajallu S; Dmytriw AA; Reierson NL; Mikoff N; Kamrowski S; Schmidt M; Davis AR; Pederson JM; Mishra HK; Touchette JC; Kallmes K
    Expert Rev Anti Infect Ther; 2021 Jun; 19(6):679-687. PubMed ID: 33187459
    [No Abstract]   [Full Text] [Related]  

  • 29. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study.
    Huang YQ; Tang SQ; Xu XL; Zeng YM; He XQ; Li Y; Harypursat V; Lu YQ; Wan Y; Zhang L; Sun QZ; Sun NN; Wang GX; Yang ZP; Chen YK
    Front Pharmacol; 2020; 11():1071. PubMed ID: 32765274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients.
    Schneider J; Jaenigen B; Wagner D; Rieg S; Hornuss D; Biever PM; Kern WV; Walz G
    PLoS One; 2021; 16(5):e0249760. PubMed ID: 33974624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial.
    Alavi Darazam I; Shokouhi S; Mardani M; Pourhoseingholi MA; Rabiei MM; Hatami F; Shabani M; Moradi O; Gharehbagh FJ; Irvani SSN; Amirdosara M; Hajiesmaeili M; Rezaei O; Khoshkar A; Lotfollahi L; Gachkar L; Dehbsneh HS; Khalili N; Soleymaninia A; Kusha AH; Shoushtari MT; Torabinavid P
    Int Immunopharmacol; 2021 Oct; 99():107969. PubMed ID: 34273635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison.
    Gagliardini R; Cozzi-Lepri A; Mariano A; Taglietti F; Vergori A; Abdeddaim A; Di Gennaro F; Mazzotta V; Amendola A; D'Offizi G; Palmieri F; Marchioni L; Piselli P; Agrati C; Nicastri E; Capobianchi MR; Petrosillo N; Ippolito G; Vaia F; Girardi E; Antinori A
    Front Pharmacol; 2021; 12():621676. PubMed ID: 33967755
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time.
    Davido B; Boussaid G; Vaugier I; Lansaman T; Bouchand F; Lawrence C; Alvarez JC; Moine P; Perronne V; Barbot F; Saleh-Mghir A; Perronne C; Annane D; De Truchis P;
    Int J Antimicrob Agents; 2020 Oct; 56(4):106129. PubMed ID: 32755653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.
    Qu J; Li GH; Wang JJ; He GF; Huang JJ; Chen Y; Qu Q; Chen XY; Lu Q
    Clin Exp Pharmacol Physiol; 2021 Feb; 48(2):203-210. PubMed ID: 33090501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
    Kalantari S; Fard SR; Maleki D; Taher MT; Yassin Z; Alimohamadi Y; Minaeian S
    J Med Virol; 2021 Dec; 93(12):6557-6565. PubMed ID: 34255369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment.
    Macías J; Pinilla A; Lao-Dominguez FA; Corma A; Contreras-Macias E; González-Serna A; Gutierrez-Pizarraya A; Fernández-Fuertes M; Morillo-Verdugo R; Trigo M; Real LM; Pineda JA
    Sci Rep; 2020 Dec; 10(1):20958. PubMed ID: 33262433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
    Padilla S; Telenti G; Guillén L; García JA; García-Abellán J; Ding C; Mora A; García-Pachón E; Gutiérrez F; Masiá M;
    Int J Antimicrob Agents; 2020 Oct; 56(4):106142. PubMed ID: 32853675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis.
    Alhumaid S; Mutair AA; Alawi ZA; Alhmeed N; Zaidi ARZ; Tobaiqy M
    Trop Med Infect Dis; 2020 Nov; 5(4):. PubMed ID: 33260553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial.
    Tabarsi P; Barati S; Jamaati H; Haseli S; Marjani M; Moniri A; Abtahian Z; Dastan A; Yousefian S; Eskandari R; Saffaei A; Monjazebi F; Vahedi A; Dastan F
    Int Immunopharmacol; 2021 Jan; 90():107205. PubMed ID: 33214093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study.
    Wong CKH; Low MCH; Kwok ACY; Lui AYC; Lau KTK; Au ICH; Xiong X; Chung MSH; Kwan MYW; Lau EHY; Cowling BJ
    Paediatr Drugs; 2022 May; 24(3):269-280. PubMed ID: 35428969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.